Nature Communications (Feb 2023)
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
- Karolina Pavic,
- Nikhil Gupta,
- Judit Domènech Omella,
- Rita Derua,
- Anna Aakula,
- Riikka Huhtaniemi,
- Juha A. Määttä,
- Nico Höfflin,
- Juha Okkeri,
- Zhizhi Wang,
- Otto Kauko,
- Roosa Varjus,
- Henrik Honkanen,
- Daniel Abankwa,
- Maja Köhn,
- Vesa P. Hytönen,
- Wenqing Xu,
- Jakob Nilsson,
- Rebecca Page,
- Veerle Janssens,
- Alexander Leitner,
- Jukka Westermarck
Affiliations
- Karolina Pavic
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Nikhil Gupta
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Judit Domènech Omella
- Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven)
- Rita Derua
- Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven)
- Anna Aakula
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Riikka Huhtaniemi
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Juha A. Määttä
- Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland and Fimlab Laboratories
- Nico Höfflin
- Faculty of Biology, Institute of Biology III, University of Freiburg
- Juha Okkeri
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Zhizhi Wang
- School of Life Science and Technology, ShanghaiTech University
- Otto Kauko
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Roosa Varjus
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Henrik Honkanen
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- Daniel Abankwa
- Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg
- Maja Köhn
- Faculty of Biology, Institute of Biology III, University of Freiburg
- Vesa P. Hytönen
- Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland and Fimlab Laboratories
- Wenqing Xu
- School of Life Science and Technology, ShanghaiTech University
- Jakob Nilsson
- The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Blegdamsvej 3B
- Rebecca Page
- Department of Chemistry and Biochemistry University of Arizona
- Veerle Janssens
- Laboratory of Protein Phosphorylation & Proteomics, Department of Cellular & Molecular Medicine, University of Leuven (KU Leuven)
- Alexander Leitner
- Department of Biology, Institute of Molecular Systems Biology, ETH Zurich
- Jukka Westermarck
- Turku Bioscience Centre, University of Turku and Åbo Akademi University
- DOI
- https://doi.org/10.1038/s41467-023-36693-9
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
Tumour suppressors are inhibited in cancers and their reactivation could provide novel therapy opportunities. Here, the authors study the structural mechanism by which human tumour suppressor Protein Phosphatase 2A is inhibited in breast cancer cells by the oncoprotein CIP2A.
